NASH Race No More Clear After AASLD Than Before
Genfit joins Intercept in Phase III, but Tobira thinks its Phase IIb study will position it well for registrational studies. Intercept expects to get to market first in primary biliary cholangitis, which could be a significant market opportunity.
You may also be interested in...
Sponsors in the hotly pursued and yet untapped field of non-alcoholic steatohepatitis think that selection of different primary or co-primary endpoints could help differentiate their programs in the competitive space.
The past few months have seen the European Medicines Agency award its much sought-after priority medicines designation to treatments for Hunter syndrome, bubble boy disease and narcolepsy.
Two products that were on the European Commission’s original list of the “top five” COVID-19 candidate therapeutics in development have been dropped from the latest “top 10” portfolio.